Clearmind Medicine Inc's Suppliers recorded an increase in sales by 0.71 % year on year in Q1 2025, sequentially sales grew by 491.79 %, while their net margin rose to 5.4 % year on year, Clearmind Medicine Inc's Suppliers improved sequentially profit margin to 491.79 %,
Clearmind Medicine Inc's Suppliers recorded an increase in sales by 0.71 % year on year in Q1 2025, sequentially sales grew by 491.79 %, while their net margin rose to 5.4 % year on year, Clearmind Medicine Inc's Suppliers improved sequentially profit margin to 5.4 %,
The company utilizes third-party contract manufacturing organizations (CMOs) for the supply and production of raw materials, components, and products required for its drug and medical device candidates. These CMOs are responsible for regulatory compliance, quality assurance, and adherence to current Good Manufacturing Practice (cGMP) standards. The company does not directly control the manufacturing process and relies on these partners to meet FDA and other regulatory requirements. Manufacturing facilities operated by CMOs are subject to inspections and approvals by the FDA and other regulatory bodies. Noncompliance or failure by CMOs to meet supply demands could delay clinical development, regulatory approval, and commercialization, adversely affecting the company's operations. Additionally, the company and its CMOs supply or manufacture materials for other companies, which introduces further regulatory risks. All parties involved in preparing product candidates for clinical trials or commercial sale must comply with extensive manufacturing regulations.
Clearmind Medicine Inc's Comment on Supply Chain
The company utilizes third-party contract manufacturing organizations (CMOs) for the supply and production of raw materials, components, and products required for its drug and medical device candidates. These CMOs are responsible for regulatory compliance, quality assurance, and adherence to current Good Manufacturing Practice (cGMP) standards. The company does not directly control the manufacturing process and relies on these partners to meet FDA and other regulatory requirements. Manufacturing facilities operated by CMOs are subject to inspections and approvals by the FDA and other regulatory bodies. Noncompliance or failure by CMOs to meet supply demands could delay clinical development, regulatory approval, and commercialization, adversely affecting the company's operations. Additionally, the company and its CMOs supply or manufacture materials for other companies, which introduces further regulatory risks. All parties involved in preparing product candidates for clinical trials or commercial sale must comply with extensive manufacturing regulations.
CMND's Suppliers Net Income grew by
CMND's Suppliers Net margin grew in Q1 to
95.67 %
5.4 %
CMND's Suppliers Net Income grew by 95.67 %
CMND's Suppliers Net margin grew in Q1 to 5.4 %
Clearmind Medicine Inc's Suppliers Sales Growth
in Q1 2025 by Industry
Sources:
Clearmind Medicine Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Clearmind Medicine Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
594.54 % 